Medical Device Regulation in Great Britain
Great Britain (England, Scotland, and Wales) regulates medical devices through the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK's departure from the European Union. The UK is transitioning from the EU CE marking system to the UKCA (UK Conformity Assessed) marking framework. The MHRA has been developing its own sovereign regulatory pathway while maintaining recognition of CE-marked devices during a transitional period.
Recent Regulatory Updates
Showing the latest 3 updates. Sign up to see more
Enhanced ILAP TDP streamlines development pathway
No substantive changes, only website updates.
UK reviews SoHO regulations, seeks stakeholder input
Sources Tracked by Qalico
Qalico continuously monitors 15 references across guidelines, regulations, and standards for Great Britain.
Regulations
Guidelines
Device Classification
Great Britain currently uses a classification system based on the EU MDR framework. Class I devices are low risk (e.g., sticking plasters, tongue depressors). Class IIa devices are low-moderate risk (e.g., blood pressure monitors, dental fillings). Class IIb devices are moderate-high risk (e.g., external defibrillators, anesthesia ventilators). Class III devices are high risk (e.g., coronary stents, total joint replacements). The MHRA is considering updates to classification rules as part of its regulatory reform.
Official classification guidance →Official Guidance Documents
Guidance on registering medical devices with the MHRA for placement on the Great Britain market.
Guidance on UKCA marking requirements and the transition from CE marking for medical devices in Great Britain.
Information on medical device safety, adverse incident reporting, and post-market surveillance in Great Britain.
The MHRA's adverse incident reporting system for medical devices and medicines, used by healthcare professionals and patients.
Standards & Key Principles
Applicable Standards
Key Principles
- Medical devices placed on the Great Britain market will ultimately require UKCA marking, though CE marking is recognized during the transitional period (currently extended).
- All manufacturers must register devices with the MHRA before placing them on the GB market.
- Non-UK manufacturers must appoint a UK Responsible Person (UKRP).
- The MHRA operates independently from EU notified bodies; UK Approved Bodies will perform conformity assessments for UKCA marking.
- The UK has its own adverse event reporting system via the Yellow Card scheme.
- The MHRA is developing new regulatory pathways that may diverge from EU MDR in areas such as software as a medical device and AI/ML-based devices.
Pre-Market Requirements
Devices must conform to UK regulations and bear the UKCA mark (or CE mark during the transitional period). UK Approved Bodies will assess conformity for higher-risk devices. The transition timeline has been extended multiple times by the MHRA.
All medical devices must be registered with the MHRA before being placed on the GB market. Registration is done through the MHRA's online device registration system.
Manufacturers based outside the UK must appoint a UK Responsible Person (UKRP) who is established in the UK and acts as the regulatory contact for the MHRA.
Full technical documentation demonstrating conformity with UK regulations is required, similar in scope to EU MDR Annexes II and III but tailored to UK-specific requirements.
Clinical evidence demonstrating safety and performance is required. Clinical investigations in GB require MHRA authorization and Research Ethics Committee approval.
Post-Market Requirements
Manufacturers must report adverse incidents to the MHRA. The Yellow Card scheme allows healthcare professionals, patients, and the public to report concerns about medical devices.
Manufacturers must maintain PMS systems to proactively monitor device safety and performance. The MHRA may request PMS data and can issue safety alerts and field safety notices.
Manufacturers must implement FSCAs when necessary and issue field safety notices. These must be reported to and coordinated with the MHRA.
Device registrations with the MHRA must be renewed periodically to maintain market access in Great Britain.
International Recognition & Reliance
CE-marked devices remain accepted on the GB market during the extended transitional period. UKCA marking will eventually be required for all devices.
The UK and Australia have established a mutual recognition framework for medical device regulatory decisions.